On­coMed racks up three straight clin­i­cal dis­as­ters as lead drug im­plodes

On­coMed $OMED just added a fresh page to its night­mare sto­ry on can­cer drug de­vel­op­ment.

Fol­low­ing up re­cent back-to-back clin­i­cal fail­ures, the biotech says that its lead drug — dem­cizum­ab, part­nered with Cel­gene — just failed a Phase II study for non-small cell lung can­cer. The drug al­ready failed a Phase II study for pan­cre­at­ic can­cer re­cent­ly. And then three weeks ago tarex­tum­ab plus chemo al­so failed a Phase II study. And that all fol­lowed a key mid-stage flop a year ago.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.